Sugi Predict

Sugi Predict / Compounds / SCHEMBL2390691

SCHEMBL2390691

SCHEMBL2390691

CCOC(=O)Cc1cc(OC)c(OC(C)C)cc1C=O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ DPP4 P27487 2/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ ERN1 O75460 3/20 0.38
▸ PRKDC P78527 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TNF P01375 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30289156 1.00 ALDH1A1 (0.44) ALDH1A1CYP2C19CYP1A2DPP4KDM4E
SCHEMBL14335628 0.87 ALDH1A1 (0.41) ALDH1A1CYP2C19KDM4EMAPTCYP3A4
SCHEMBL8282635 0.85 CYP3A4 (0.51) ALDH1A1DPP4KDM4EMAPTCYP3A4
SCHEMBL2391352 0.80 DPP4 (0.36) ALDH1A1CYP2C19DPP4KDM4EMAPT
SCHEMBL2391358 0.80 DPP4 (0.36) ALDH1A1CYP2C19DPP4KDM4EMAPT
SCHEMBL2391348 0.80 DPP4 (0.36) ALDH1A1CYP2C19DPP4KDM4EMAPT
SCHEMBL9039124 0.78 ALDH1A1 (0.52) ALDH1A1CYP2C19KDM4EMAPTCYP3A4
SCHEMBL31063281 0.74 HSD17B10 (0.52) ALDH1A1DPP4KDM4EMAPTMAPK1
SCHEMBL2391813 0.74 ALDH1A1 (0.53) ALDH1A1CYP2C19CYP1A2MAPTCYP3A4
SCHEMBL30289115 0.73 P2RX3 (0.40) ALDH1A1DPP4MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411432-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2022-12-29 — — US disclosed
US-11192898-B2 MDM2 protein degraders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-12-07 — — US disclosed
US-20190127387-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2019-05-02 — — US disclosed
WO-2017176957-A1 MDM2 PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-12 — — WO disclosed
US-9073898-B2 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2015-07-07 — — US disclosed
US-9073898-B2 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2015-07-07 — — US disclosed
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 — — US disclosed
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 — — US disclosed
EP-2721008-B1 HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS NOVARTIS AG (CH) 2015-04-29 — — EP disclosed
EP-2721008-B1 HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS NOVARTIS AG (CH) 2015-04-29 — — EP disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
WO-2012175520-A1 HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2012-12-27 — — WO disclosed
WO-2012175520-A1 HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2012-12-27 — — WO disclosed
EP-2516009-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES Novartis AG (CH) 2012-10-31 — — EP disclosed
WO-2012066095-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
WO-2012066095-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192898-B2 MDM2 protein degraders MDM2, TP53, TP53BP1 ALDH1A1 300/4885CYP2C19 3695/4885CYP1A2 1726/4885
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 ALDH1A1 3726/4885CYP2C19 989/4885CYP1A2 916/4885
US-20220411432-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 ALDH1A1 300/4885CYP2C19 3695/4885CYP1A2 1726/4885
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction MDM4, TP53, TP53BP1 ALDH1A1 4048/4885CYP2C19 3130/4885CYP1A2 3350/4885
US-20190127387-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 ALDH1A1 300/4885CYP2C19 3695/4885CYP1A2 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.